Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma.
Journal: Cancer letters
Published: March 27, 2024
The past, present, and future of liver cancer research in China.
Journal: Cancer letters
Published: June 07, 2023
Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors.
Journal: Journal of clinical pharmacology
Published: April 29, 2022
Research trends of cancer metabolism: analysis from a Chinese perspective.
Journal: Cancer communications (London, England)
Published: January 11, 2022
The 2010-2020 National Natural Science Foundation of China: Radiation Therapy.
Journal: Current medical science
Published: October 12, 2021
Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
Journal: Leukemia & lymphoma
Published: July 25, 2020
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
Journal: Pharmaceutical research
Published: June 17, 2020
Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials.
Journal: Journal of clinical pharmacology
Published: June 13, 2020
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Journal: Cancer chemotherapy and pharmacology
Published: March 20, 2020
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: August 12, 2019
Last Updated: 09/26/2026